RAIN:NASDAQ, Rain Enhancement Technologies Holdco, Inc.
RAIN stock overview
Rain Enhancement Technologies Holdco, Inc. (RAIN:NASDAQ) closed at $0.633 on October 19, 2026,
up 0.96% on the day.
The stock trades 92.6% below its 52-week high of $8.52
and 5.8% above its 52-week low of $0.598.
Over the past year, it lost 88.8%.
Rain Enhancement Technologies Holdco, Inc. is part of the Health Care sector.
Key figures
- Price
- $0.633
- Day change
- +0.96%
- Volume
- 37,634
- Average volume
- 1,700,193
- Market cap
- 7M+
- 52-week range
- $0.598 – $8.52
- 50-day average
- $0.839
- 200-day average
- $1.98
Price action over the past year
In 252 trading sessions since October 17, 2025, RAIN closed higher on 94 days (37%).
Its best day was September 22, 2026 (+54.31%) and its worst was December 31, 2025 (-28.17%).
The stock moved 10% or more in a single session 44 times.
It opened at least 5% above the previous day's high 4 times.
Recent signals
RAIN news
-
Oct 19, 2026:
Early Commercialization Positions RAIN as Potentially Disruptive Provider – Downloadable Initiation Report
-
Oct 19, 2026:
Early Commercialization Positions RAIN as Potentially Disruptive Provider – Initiation Report
-
Oct 12, 2026:
Targeting Water Scarcity: Rain Enhancement Technologies CEO Randy Seidl, Live at Nasdaq
-
Sep 23, 2026:
Rain Enhancement Technologies and Tensor Networks Sign Binding Letter of Intent for Strategic Business Combination
-
Sep 9, 2026:
Rain Enhancement Technologies to Present at H.C. Wainwright 28th Annual Global Investment Conference
-
Sep 1, 2026:
Rain Enhancement Technologies Announces Agreement with California Highway Patrol to Test Fog Mitigation Technology
-
Aug 21, 2026:
Rain Enhancement Technologies Recognized With 2026 "AgTech Climate Innovation of the Year" by AgTech Breakthrough
-
Aug 12, 2026:
Rain Enhancement Technologies Reports Business Progress, Hosts Webcast Today
About Rain Enhancement Technologies Holdco, Inc.
Rain Therapeutics Inc is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which they are able to genetically select patients they believe will most likely benefit. Its lead product candidate, RAIN-32 is a small molecule, oral inhibitor of mouse double minute 2, which is oncogenic in numerous cancers.
Similar stocks
Find more stocks like RAIN with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.